Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 18, 2014 - Issue 11
Submit an article Journal homepage
657
Views
20
CrossRef citations to date
0
Altmetric
Reviews

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

Wen-Yue LiuThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, School of the First Clinical Medical Sciences, Wenzhou 325000, China
,
Sha HuangThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, School of the First Clinical Medical Sciences, Wenzhou 325000, China
,
Ke-Qing ShiThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, Institute of Hepatology, Wenzhou 325000, China
,
Chen-Chen ZhaoThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, School of the First Clinical Medical Sciences, Wenzhou 325000, China
,
Li-Li ChenThe First Affiliated Hospital of Wenzhou Medical University, Department of Intensive Care Unit, Wenzhou 325000, China
,
Martin BraddockGlobal Medicines Development, AstraZeneca R&D, Loughborough, UK
,
Yong-Ping ChenThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, Institute of Hepatology, Wenzhou 325000, China
,
Wen-Ke FengUniversity of Louisville School of Medicine, Alcohol Research Center, Department of Medicine, Louisville, KY, USA
&
Ming-Hua ZhengThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, Institute of Hepatology, Wenzhou 325000, China
, MD PhD show all
Pages 1305-1313 | Published online: 31 Jul 2014

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Ghada M El Sagheer, Asmaa K Ahmad, Aliaa S Abd-ElFattah, Zienab M Saad & Lamia Hamdi. (2018) A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. Clinical and Experimental Gastroenterology 11, pages 415-422.
Read now
Fa-Ling Wu, Wen-Yue Liu, Sven Van Poucke, Martin Braddock, Wei-Min Jin, Jian Xiao, Xiao-Kun Li & Ming-Hua Zheng. (2016) Targeting endoplasmic reticulum stress in liver disease. Expert Review of Gastroenterology & Hepatology 10:9, pages 1041-1052.
Read now
Wen-Yue Liu, Dong-Mei Xie, Gui-Qi Zhu, Gui-Qian Huang, Yi-Qian Lin, Li-Ren Wang, Ke-Qing Shi, Bin Hu, Martin Braddock, Yong-Ping Chen & Ming-Hua Zheng. (2015) Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opinion on Therapeutic Targets 19:5, pages 675-685.
Read now
Zhong-Min Liu, Miao Hu, Paul Chan & Brian Tomlinson. (2015) Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opinion on Investigational Drugs 24:5, pages 611-621.
Read now

Articles from other publishers (16)

Wei-Chin Hung, Teng-Hung Yu, Chao-Ping Wang, Chia-Chang Hsu, Yung-Chuan Lu, Ching-Ting Wei, Fu-Mei Chung, Yau-Jiunn Lee, Cheng-Ching Wu & Wei-Hua Tang. (2022) Fibroblast growth factor 21 is associated with widening QRS complex and prolonged corrected QT interval in patients with stable angina. BMC Cardiovascular Disorders 22:1.
Crossref
Guihai Wu, Shenglin Wu, Jingyi Yan, Shanshan Gao, Jinxiu Zhu, Minghui Yue, Zexin Li & Xuerui Tan. (2022) Fibroblast Growth Factor 21 Predicts Short-Term Prognosis in Patients With Acute Heart Failure: A Prospective Cohort Study. Frontiers in Cardiovascular Medicine 9.
Crossref
Lisa G. Riley, Michael Nafisinia, Minal J. Menezes, Reta Nambiar, Andrew Williams, Elizabeth H. Barnes, Arthavan Selvanathan, Kate Lichkus, Drago Bratkovic, Joy Yaplito-Lee, Kaustuv Bhattacharya, Carolyn Ellaway, Maina Kava, Shanti Balasubramaniam & John Christodoulou. (2022) FGF21 outperforms GDF15 as a diagnostic biomarker of mitochondrial disease in children. Molecular Genetics and Metabolism 135:1, pages 63-71.
Crossref
Yijun Wang, Danfei Liu, Tongyue Zhang & Limin Xia. (2021) FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers 13:6, pages 1360.
Crossref
Jing Yang, Jun Gao, Wenchen Yu, Ruobing Hao, Jungang Fan & Jie Wei. (2020) The effects and mechanism of Aronia melanocarpa Elliot anthocyanins on hepatic fibrosis. Journal of Functional Foods 68, pages 103897.
Crossref
Ana Luisa Cardoso, Adelaide Fernandes, Juan Antonio Aguilar-Pimentel, Martin Hrabě de Angelis, Joana Ribeiro Guedes, Maria Alexandra Brito, Saida Ortolano, Giovambattista Pani, Sophia Athanasopoulou, Efstathios S. Gonos, Markus Schosserer, Johannes Grillari, Pärt Peterson, Bilge Guvenc Tuna, Soner Dogan, Angelika Meyer, Ronald van Os & Anne-Ulrike Trendelenburg. (2018) Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases. Ageing Research Reviews 47, pages 214-277.
Crossref
Lichen Bao, Jun Yin, Wen Gao, Qun Wang, Wenbing Yao & Xiangdong Gao. (2018) A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. British Journal of Pharmacology 175:16, pages 3379-3393.
Crossref
Jun Yin, Lichen Bao, Rong Chen, Wen Gao, Xiangdong Gao & Wenbing Yao. (2018) Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis. Biochimie 151, pages 166-175.
Crossref
Kyong Joo Lee, Yoon Ok Jang, Seung-Kuy Cha, Moon Young Kim, Kyu-Sang Park, Young Woo Eom & Soon Koo Baik. (2018) Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways. Gut and Liver 12:4, pages 449-456.
Crossref
Yufan Zang, Li Fan, Jihua Chen, Ruixue Huang & Hong Qin. (2018) Improvement of Lipid and Glucose Metabolism by Capsiate in Palmitic Acid-Treated HepG2 Cells via Activation of the AMPK/SIRT1 Signaling Pathway. Journal of Agricultural and Food Chemistry 66:26, pages 6772-6781.
Crossref
Bilin XuTian ShenLin ChenJuan XiaCuiping ZhangHongping WangMing YuTao Lei. (2017) The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms. Medical Science Monitor 23, pages 1363-1370.
Crossref
Dawei Li, Tianfei Lu, Conghuan Shen, Yuan Liu, Jiang Zhang, Yuhua Shan, Yi Luo, Zhifeng Xi, Bijun Qiu, Qimin Chen, Jianjun Zhang & Qiang Xia. (2016) Expression of fibroblast growth factor 21 in patients with biliary atresia. Cytokine 83, pages 13-18.
Crossref
Zhifei Wang, Yan Leng, Junyu Wang, Hsiao-Mei Liao, Joel Bergman, Peter Leeds, Alan Kozikowski & De-Maw Chuang. (2016) Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation. Scientific Reports 6:1.
Crossref
Jun Zhang & Yang Li. (2015) Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders. Frontiers in Endocrinology 6.
Crossref
C. Lisa Kurtz, Emily E. Fannin, Cynthia L. Toth, Daniel S. Pearson, Kasey C. Vickers & Praveen Sethupathy. (2015) Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Scientific Reports 5:1.
Crossref
Youngmin A Lee, Michael C Wallace & Scott L Friedman. (2015) Pathobiology of liver fibrosis: a translational success story. Gut 64:5, pages 830-841.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.